Entrada Therapeutics, Inc. - Common Stock (TRDA)
13.99
+0.43 (3.17%)
Entrada Therapeutics Inc is a biotechnology company focused on advancing a new class of therapeutics designed to treat a range of severe diseases
The company utilizes its proprietary protein cargo platform to develop treatments that enhance the delivery of therapeutic proteins directly into cells, aiming to address unmet medical needs in various fields, including rare and complex diseases. Entrada prioritizes innovation in drug delivery systems, striving to improve patient outcomes through targeted and efficient therapies that can potentially transform the treatment landscape for conditions where traditional methods fall short.
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_3.png?width=1200&height=800&fit=crop)
Via Benzinga · November 6, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 13, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · April 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/11/americas_car-mart_-_logo.jpg?width=1200&height=800&fit=crop)
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.
Via Benzinga · April 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/22/image31.jpeg?width=1200&height=800&fit=crop)
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via Benzinga · March 22, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 27, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 23, 2023
![](https://cdn.benzinga.com/files/images/story/2023/11/22/trda.png?width=1200&height=800&fit=crop)
Entrada Therapeutics Inc (NASDAQTRDA) shares are trading lower after the company announced updates on ENTR-601-44 in
Via Benzinga · November 22, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 22, 2023
![](/next-assets/images/schema-image-default.png)
Via Benzinga · April 3, 2023
![](/next-assets/images/schema-image-default.png)
Via Benzinga · March 9, 2023
![](/next-assets/images/schema-image-default.png)
Via Benzinga · February 16, 2023
![](https://cdn.benzinga.com/files/images/story/2023/02/15/image_3.jpg?width=1200&height=800&fit=crop)
Gainers Sera Prognostics, Inc. (NASDAQSERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.
Via Benzinga · February 15, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_2975.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 15, 2023
![](/next-assets/images/schema-image-default.png)
Via Benzinga · February 14, 2023
![](https://cdn.benzinga.com/files/images/story/2022/12/20/image48.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Tuesday.
Via Benzinga · December 20, 2022
![](https://cdn.benzinga.com/files/images/story/2022/12/20/image_3.jpg?width=1200&height=800&fit=crop)
Gainers IceCure Medical Ltd (NASDAQICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.
Via Benzinga · December 20, 2022
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · December 20, 2022
![](https://cdn.benzinga.com/files/images/story/2022/12/20/image21.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mixed midway through trading, with the S&P 500 and the Nasdaq Composite moving lower on Tuesday.
Via Benzinga · December 20, 2022
![](https://cdn.benzinga.com/files/images/story/2022/12/20/image15_0.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via Benzinga · December 20, 2022
![](https://cdn.benzinga.com/files/images/story/2022/12/20/image-entrada_therapeutics.jpg?width=1200&height=800&fit=crop)
Gainers IceCure Medical Ltd (NASDAQICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.
Via Benzinga · December 20, 2022
![](https://cdn.benzinga.com/files/images/story/2022/12/20/image-nike.png?width=1200&height=800&fit=crop)
With US stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Via Benzinga · December 20, 2022